Hydrochlorothiazide for Kidney Stone Recurrence Prevention

NCT03057431 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

416

Enrollment

OTHER

Sponsor class

Conditions

Nephrolithiasis

Interventions

DRUG: Placebo oral capsule
DRUG: 12.5 mg hydrochlorothiazide
DRUG: 25.0 mg hydrochlorothiazide
DRUG: 50.0 mg hydrochlorothiazide

Sponsor

Insel Gruppe AG, University Hospital Bern